Review
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 14, 2023; 29(2): 272-285
Published online Jan 14, 2023. doi: 10.3748/wjg.v29.i2.272
Advancing the precision management of inflammatory bowel disease in the era of omics approaches and new technology
Xin-Yu Liu, Hao Tang, Qing-Yang Zhou, Yan-Lin Zeng, Dan Chen, Hui Xu, Yue Li, Bei Tan, Jia-Ming Qian
Xin-Yu Liu, Qing-Yang Zhou, Yan-Lin Zeng, Hui Xu, Yue Li, Bei Tan, Jia-Ming Qian, Department of Gastroenterology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing 100730, China
Xin-Yu Liu, Eight-year Medical Doctor Program, Peking Union Medical College & Chinese Academy of Medical Science, Beijing 100730, China
Hao Tang, Department of Internal Medicine, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing 100730, China
Yan-Lin Zeng, School of Medicine, Tsinghua University, Beijing 100084, China
Dan Chen, Department of Gastroenterology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing 100730, China
Author contributions: Liu XY and Tan B designed the outline of the manuscript; Liu XY drafted the manuscript; Tang H, Zhou QY, Zeng YL, Chen D, Xu H, and Li Y contributed to the editing of the manuscript and reviewed the literature; Tan B revised the manuscript and provided funding support; Qian JM supervised and supported the study; all authors have read and approve the final manuscript.
Supported by the Youth Program of National Natural Science Foundation of China, No. 82000526; the National High Level Hospital Clinical Research Funding, No. 2022-PUMCH-A-072; and the National College Students’ Innovation and Entrepreneurship Training Program, No. 2022zglc06083.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bei Tan, MD, Associate Professor, Department of Gastroenterology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, No. 1 Shuaifuyuan, Dongcheng District, Beijing 100730, China. tanbei0626@aliyun.com
Received: September 23, 2022
Peer-review started: September 23, 2022
First decision: November 18, 2022
Revised: December 1, 2022
Accepted: December 21, 2022
Article in press: December 21, 2022
Published online: January 14, 2023
Abstract

There is great heterogeneity among inflammatory bowel disease (IBD) patients in terms of pathogenesis, clinical manifestation, response to treatment, and prognosis, which requires the individualized and precision management of patients. Many studies have focused on prediction biomarkers and models for assessing IBD disease type, activity, severity, and prognosis. During the era of biologics, how to predict the response and side effects of patients to different treatments and how to quickly recognize the loss of response have also become important topics. Multiomics is a promising area for investigating the complex network of IBD pathogenesis. Integrating numerous amounts of data requires the use of artificial intelligence.

Keywords: Inflammatory bowel diseases, Precision management, Multiomics, Artificial intelligence

Core Tip: Inflammatory bowel diseases (IBDs) exhibit different pathogeneses and clinical manifestations. Making precise and appropriate therapeutic decisions according to the condition of each patient remains challenging. We summarize the clustering strategies, the approaches used to apply multiomics and artificial intelligence to IBD precision management.